Stocks Alert: Mead Johnson Nutrition Company (MJN), Pfizer Inc. (PFE), Nielsen Holdings plc (NLSN)

Mead Johnson Nutrition Company (MJN) retreated with the stock falling -0.18% or $-0.16 to close at $88.04 on active trading volume of 7.87M compared its three months average trading volume of 3.06M. The Glenview Illinois 60026 based company operating under the Processed & Packaged Goods industry has been trending up for the last 52 weeks, with the shares price now 23.31% up for the period and up by 24.42% so far this year. With price target of $81.7 and a 27.13% rebound from 52-week low, Mead Johnson Nutrition Company has plenty of upside potential, making it a hold with a view buy.

Mead Johnson Nutrition Company manufactures, distributes, and sells infant formulas, children’s nutrition, and other nutritional products. It offers routine infant formula products as a breast milk substitute for healthy infants for use as the infant’s source of nutrition, as well as a supplement to breastfeeding under the Enfamil Premium, Enfapro Premium, Enfalac A+, and Enfamil A+ names; and solutions products to address common feeding tolerance problems, including spit-up, fussiness, gas, and lactose intolerance under the Enfamil Gentlease, Enfamil A.R., Enfamil ProSobee, and Enfamil LactoFree names. The company also provides specialty formula products, including formulas for addressing special medical needs, such as Nutramigen for cow’s milk protein allergies, as well as Puramino, an amino acid formula for cow’s milk protein allergies or multiple other food allergies; Enfamil Premature to meet the needs of premature and low birth weight infants; EnfaCare, a hypercaloric formula for premature babies at home; and produces medical foods for nutritional management of individuals with rare, inborn errors of metabolism comprising maple syrup urine disease and phenylketonuria. In addition, it offers children’s nutrition products comprising products for meeting children’s nutritional needs at toddlers and older children stage, as well as offer milk modifiers under the Enfagrow, Sustagen, Lactum, ChocoMilk, and Cal-C-Tose names; a range of other products, including pre-natal and post-natal nutritional supplements for expectant and nursing mothers under the Expecta and EnfaMama names; and pediatric vitamin products under the Enfamil Poly-Vi-Sol name, as well as multivitamins and iron supplements for infants. The company sells its products to mothers, health care professionals, and retailers in approximately 50 countries in Asia, North America, Latin America, and Europe. Mead Johnson Nutrition Company was founded in 1905 and is headquartered in Glenview, Illinois.

Pfizer Inc. (PFE) gained $0.14 to close the day at a new closing price of $32.75, a 0.43% increase in value from its previous closing price that moved the stock 18.28% above its 52 week low of $28.74. A total of 22.89M shares exchanged hands during the day compared with its three month average trading volume of 24.94M. The stock, which fluctuated between $32.35 and $32.77 during the day, currently situated -9.89% below its 52 week high. The stock is up by 1.73% in the past one month and up by 1.51% over the past three months. With a one year target estimate of $37.48 and RSI of 65, the stock still has upside potential, making it a hold for now.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, Transgene S.A., Edelris SAS, IGNITE Immunotherapy Inc., and AbCellera Biologics Inc.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Nielsen Holdings plc (NLSN) shares were down in last trading by -0.47% to $44.77. It experienced higher than average volume on day. The stock increased in value by almost 6.95% over the past week and grew 5.69% in the past month. It is currently trading 6.05% above its 50 day moving average and -8.19% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -18.93% decrease in value from its one year high of $55.94. The RSI indicator value of 71.11, lead us to believe that it may reverse gains in the near term.

Nielsen Holdings plc operates as an information and measurement company. The company provides media and marketing information, analytics, and manufacturer and retailer expertise about what and where consumers buy, read, watch and listen. Its Buy segment provides retail transactional measurement data, consumer behavior information, and analytics primarily to businesses in the consumer packaged goods industry. This segment provides data on retail measurement services, such as market share and competitive sales volumes; insights into distribution, pricing, merchandising, and promotion; consumer panel measurement, which offers insight into shopper behavior and customer segmentation; and consumer intelligence and analytical services for decision making in development and marketing cycles. The company’s Watch segment provides viewership and listening data, and analytics primarily to the media and advertising industries for television, radio, digital and mobile viewing, and listening platforms. It offers television audience measurement services, including more than one screen, unduplicated reach, cause and effect analysis, and program viewing behavior testing; audio audience measurement services; digital audience measurement services, such as digital media and market research, audience analytics, and social media measurement; mobile measurement services comprising measurement and consumer research for telecom and media companies; and advertiser solutions. The company was formerly known as Nielsen N.V. and changed its name to Nielsen Holdings plc in August 2015. The company was founded in 1923 and is headquartered in Oxford, the United Kingdom.

 

3 Notable Runners: Pfizer Inc. (PFE), Microsoft Corporation (MSFT), Microchip Technology Incorporated (MCHP)

Pfizer Inc. (PFE) failed to extend gains with the stock declining -0.09% or $-0.03 to close the day at $32.35 on lower than average trading volume of 19.3M shares, compared to its three month average trading volume of 25.91M. The New York New York 10017 based company has been underperforming the drug manufacturers – major companies by 1.7508% for last three months and its recent gains have pushed the stock slightly up 0.61% YTD, versus the drug manufacturers – major industry which is up 2.05% for the same period. The RSI of 59.62 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, Transgene S.A., Edelris SAS, IGNITE Immunotherapy Inc., and AbCellera Biologics Inc.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Microsoft Corporation (MSFT) had a light trading with around 18.17M shares changing hands compared to its three month average trading volume of 25.97M. The stock traded between $63.97 and $64.3 before closing at the price of $64 with -0.09% change on the day. The Redmond Washington 98052 based company is currently trading 35.55% above its 52 week low of $48.04 and -2.9% below its 52 week high of $65.91. Both the RSI indicator and target price of 55.68 and $68.97 respectively, lead us to believe that it should be put on hold over the coming weeks.

Microsoft Corporation, a technology company, develops, licenses, and supports software products, services, and devices worldwide. The company’s Productivity and Business Processes segment offers Office 365 commercial products and services for businesses, including Office, Exchange, SharePoint, and Skype, as well as related Client Access Licenses (CALs); Office 365 consumer services, such as Skype, Outlook.com, and OneDrive; Dynamics business solutions, such as financial management, customer relationship management, supply chain management, and analytics applications for small and mid-size businesses, large organizations, and divisions of enterprises; and LinkedIn online professional network. Its Intelligent Cloud segment licenses server products and cloud services, such as SQL Server, Windows Server, Visual Studio, System Center, and related CALs, as well as Azure, a cloud platform with computing, networking, storage, database, and management services; and enterprise services, such as Premier Support and Microsoft Consulting that assist in developing, deploying, and managing Microsoft server and desktop solutions, as well as provide training and certification to developers and IT professionals on Microsoft products. The company’s More Personal Computing segment comprises Windows OEM, volume, and other non-volume licensing of the Windows operating system, as well as patent licensing, Windows Embedded, MSN display advertising, and Windows Phone licensing system; devices, including Microsoft Surface, phones, and PC accessories; and search advertising, including Bing and Bing Ads. This segment also provides gaming platforms, including Xbox hardware, Xbox Live, video games, and third-party video games. The company markets and distributes its products through original equipment manufacturers (OEM), distributors, and resellers, as well as through online and Microsoft retail stores. Microsoft Corporation was founded in 1975 and is headquartered in Redmond, Washington.

Microchip Technology Incorporated (MCHP) traded within a range of $69.76 to $71.02 after opening the day at $70.54. The company has seen its stock increase in value by 10.52% so far this year. The stock was down close to -0.04% on active volume in last trading session and closed at $70.9 per share. After the recent fall, the stock is currently holding -7.32% below its 52 week high of $76.5 and 86.79% above its 12-month low of $40.81. The shares are up by over 10.86% in the last three months, and the RSI indicator value of 60.91 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Microchip Technology Incorporated develops, manufactures, and sells semiconductor products for various embedded control applications. The company offers microcontrollers, such as 8-bit, 16-bit, and 32-bit microcontrollers under the PIC brand name; and microcontrollers for automotive networking, computing, lighting, power supplies, motor control, wired connectivity, and wireless connectivity. It also provides development tools that enable system designers to program PIC microcontrollers for specific applications; analog, interface, mixed signal, and timing products comprising power management, linear, mixed-signal, high-voltage, thermal management, RF, drivers, safety and security, USB, Ethernet, wireless, and other interface products; and memory products consisting of serial electrically erasable programmable read-only memory, serial flash memories, parallel flash memories, and serial SRAM memories for the production of very small footprint devices. In addition, the company licenses its SuperFlash embedded flash and Smartbits one time programmable NVM technologies to foundries, integrated device manufacturers, and design partners for use in the manufacture of microcontroller products, gate array, RF, and analog products that require embedded non-volatile memory, as well as provides engineering services. It serves automotive, communications, computing, consumer, office automation, telecommunication, aerospace, defense, safety, security, medical, and industrial control markets. The company sells its products through a network of direct sales personnel and distributors in the Americas, Europe, and Asia. Microchip Technology Incorporated was founded in 1989 and is headquartered in Chandler, Arizona.

 

Three Movers to Watch for: Cognizant Technology Solutions Corporation (CTSH), Cisco Systems, Inc. (CSCO), Pfizer Inc. (PFE)

Cognizant Technology Solutions Corporation (CTSH) grew with the stock adding 4.95% or $2.66 to close at $56.45 on light trading volume of 20.66M compared its three months average trading volume of 6.36M. The Teaneck New Jersey 07666 based company operating under the Business Software & Services industry has been trending up for the last 52 weeks, with the shares price now 7.87% up for the period and up by 0.75% so far this year. With price target of $63.81 and a 24.23% rebound from 52-week low, Cognizant Technology Solutions Corporation has plenty of upside potential, making it a hold with a view buy.

Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates through four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other. Its consulting and technology services include IT strategy consulting, program management consulting, operations improvement consulting, strategy consulting, and business consulting services; and application design and development, systems integration, enterprise resource planning, and customer relationship management implementation services. The company also offers enterprise information management services, such as strategic, advisory, and management consulting; enterprise data management; descriptive analytics/business intelligence; strategic corporate performance management; and packaged analytics services, as well as big data services that assist clients in managing and deriving actionable insights. In addition, it provides application testing services; and develops, licenses, implements, and supports proprietary and third-party software products, as well as offers digital technologies services. Further, the company offers outsourcing services, such as application maintenance services; IT infrastructure services; and business process services, including clinical data management, pharmacovigilance, equity research support, commercial operations, and order management. It serves various industries, including banking and insurance; healthcare and life sciences; manufacturing and logistics; retail, travel, and hospitality; consumer goods; communications; information, media, and entertainment; and technology. The company markets and sells services through its professional staff, senior management, and direct sales personnel. Cognizant Technology Solutions Corporation was founded in 1998 and is headquartered in Teaneck, New Jersey.

Cisco Systems, Inc. (CSCO) dropped $-0.18 to close the day at a new closing price of $31.27, a -0.57% decrease in value from its previous closing price that moved the stock 44.18% above its 52 week low of $24.09. A total of 20.37M shares exchanged hands during the day compared with its three month average trading volume of 22.71M. The stock, which fluctuated between $31.25 and $31.55 during the day, currently situated -1.17% below its 52 week high. The stock is up by 3.61% in the past one month and up by 1.93% over the past three months. With a one year target estimate of $33.26 and RSI of 65.29, the stock still has upside potential, making it a hold for now.

Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol (IP) based networking and other products related to the communications and information technology industry worldwide. It provides switching products, including fixed-configuration and modular switches, and storage products that provide connectivity to end users, workstations, IP phones, wireless access points, and servers; and next-generation network routing products that interconnect public and private wireline and mobile networks for mobile, data, voice, and video applications. The company also offers service provider video infrastructure, including set-top boxes, cable/telecommunications access products, and cable modems; and video software and solutions. In addition, it provides collaboration products comprising unified communications products, conferencing products, collaboration endpoints, and business messaging products; data center products, such as blade and rack servers, modular servers, fabric interconnects, software, and server access virtualization solutions; security products, including network and data center security, advanced threat protection, Web and email security, access and policy, unified threat management, and advisory, integration, and managed services; and other products, such as emerging technologies and other networking products. Further, the company offers wireless products consisting of wireless access points; network managed services; and standalone, switch-converged, and cloud managed solutions. Additionally, it provides technical support services and advanced services. The company serves businesses of various sizes, public institutions, governments, and communications service providers. Cisco Systems, Inc. sells its products directly, as well as through channel partners, such as systems integrators, service providers, other resellers, and distributors. The company was founded in 1984 and is headquartered in San Jose, California.

Pfizer Inc. (PFE) shares were up in last trading by 0.19% to $32.14. It experienced lighter than average volume on day. The stock increased in value by almost 1.48% over the past week and fell -3% in the past month. It is currently trading 0.79% above its 50 day moving average and -2.43% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -11.57% decrease in value from its one year high of $37.39. The RSI indicator value of 59.54, lead us to believe that it is a hold for now.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, Transgene S.A., Edelris SAS, IGNITE Immunotherapy Inc., and AbCellera Biologics Inc.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

 

Stocks Trend Analysis: Advanced Micro Devices, Inc. (AMD), Cabot Oil & Gas Corporation (COG), Pfizer Inc. (PFE)

Advanced Micro Devices, Inc. (AMD) managed to rebound with the stock climbing 11.36% or $1.39 to close the day at $13.63 on light trading volume of 139.87M shares, compared to its three month average trading volume of 52.4M. The Sunnyvale California 94088 based company has been outperforming the semiconductor – broad line group over the past 52 weeks, with the stock gaining 588.38%, compared to the industry which has advanced 49.46% over the same period. With RSI of 78.14, the stock should still continue to rise and get closer to its one year target estimate of $10.96, making it a hold for now.

Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily include x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products. It provides x86 microprocessors for desktop PCs under the AMD A-Series, AMD E-Series, AMD FX CPU, AMD Athlon CPU and APU, AMD Sempron APU and CPU, and AMD Pro A-Series APU brands; and microprocessors for notebook and 2-in-1s under the AMD A-Series, AMD E-Series, AMD C-Series, AMD Z-Series, AMD FX APU, AMD Phenom, AMD Athlon CPU and APU, AMD Turion, and AMD Sempron APU and CPU brands. The company also offers chipsets with and without integrated graphics features for desktop, notebook PCs, and servers, as well as controller hub-based chipsets for its APUs under the AMD brand; and AMD PRO mobile and desktop processors. In addition, it provides discrete desktop graphics products and discrete GPUs for notebooks under the AMD Radeon brand; professional graphics products under the AMD FirePro brand; and customer-specific solutions based on AMD’s CPU, GPU, and multi-media technologies. Further, the company offers microprocessors for server platforms under the AMD Opteron; embedded processor solutions for interactive digital signage, casino gaming, and medical imaging under the AMD Opteron, AMD Athlon, AMD Sempron, AMD Geode, AMD R-Series, and G-Series brands; and semi-custom SoC products that power the Sony Playstation 4 and Microsoft Xbox One game consoles. Advanced Micro Devices, Inc. sells its products through its direct sales force, independent distributors, and sales representatives. The company serves original equipment manufacturers, original design manufacturers, system builders, and independent distributors. Advanced Micro Devices, Inc. was founded in 1969 and is headquartered in Sunnyvale, California.

Cabot Oil & Gas Corporation (COG) grew with the stock adding 10.73% or $2.3 to close at $23.73 on light trading volume of 26.58M compared its three months average trading volume of 6.41M. The Houston Texas 77024 based company operating under the Independent Oil & Gas industry has been trending up for the last 52 weeks, with the shares price now 15.26% up for the period and up by 1.68% so far this year. With price target of $27.9 and a 28.86% rebound from 52-week low, Cabot Oil & Gas Corporation has plenty of upside potential, making it a hold with a view buy.

Cabot Oil & Gas Corporation, an independent oil and gas company, develops, exploits, explores for, produces, and markets natural gas, oil, and natural gas liquids in the United States. The company primarily focuses on the Marcellus Shale in northeast Pennsylvania with approximately 200,000 net acres in the dry gas window of the play; and the Eagle Ford Shale in south Texas with approximately 85,500 net acres in the oil window of the play. It also transports, stores, gathers, and purchases natural gas for resale. The company sells its natural gas to industrial customers, local distribution companies, and gas marketers through gathering systems and pipelines, as well as to intrastate pipelines, natural gas processors, and marketing companies. As of December 31, 2015, it had proved reserves of approximately 8,190 billion cubic feet of natural gas equivalent. The company was founded in 1989 and is headquartered in Houston, Texas.

Pfizer Inc. (PFE) continued its upward trend with the stock climbing 0.44% or $0.14 to close the day at $32.23 on lower than average trading volume of 24.35M shares, compared to its three month average trading volume of 27.98M. The New York New York 10017 based company has been outperforming the drug manufacturers – major companies by 9.9606% for last three months and its recent gains have pushed the stock slightly up 0.24% YTD, versus the drug manufacturers – major industry which is up 0.74% for the same period. The RSI of 59.83 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, Transgene S.A., Edelris SAS, IGNITE Immunotherapy Inc., and AbCellera Biologics Inc.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

 

Three Movers to Watch for: Mead Johnson Nutrition Company (MJN), Pfizer Inc. (PFE), General Electric Company (GE)

Mead Johnson Nutrition Company (MJN) grew with the stock adding 21.41% or $14.88 to close at $84.38 on active trading volume of 24.46M compared its three months average trading volume of 1.84M. The Glenview Illinois 60026 based company operating under the Processed & Packaged Goods industry has been trending up for the last 52 weeks, with the shares price now 25.07% up for the period and up by 19.25% so far this year. With price target of $76.67 and a 29.33% rebound from 52-week low, Mead Johnson Nutrition Company has plenty of upside potential, making it a hold with a view buy.

Mead Johnson Nutrition Company manufactures, distributes, and sells infant formulas, children’s nutrition, and other nutritional products. It offers routine infant formula products as a breast milk substitute for healthy infants for use as the infant’s source of nutrition, as well as a supplement to breastfeeding under the Enfamil Premium, Enfapro Premium, Enfalac A+, and Enfamil A+ names; and solutions products to address common feeding tolerance problems, including spit-up, fussiness, gas, and lactose intolerance under the Enfamil Gentlease, Enfamil A.R., Enfamil ProSobee, and Enfamil LactoFree names. The company also provides specialty formula products, including formulas for addressing special medical needs, such as Nutramigen for cow’s milk protein allergies, as well as Puramino, an amino acid formula for cow’s milk protein allergies or multiple other food allergies; Enfamil Premature to meet the needs of premature and low birth weight infants; EnfaCare, a hypercaloric formula for premature babies at home; and produces medical foods for nutritional management of individuals with rare, inborn errors of metabolism comprising maple syrup urine disease and phenylketonuria. In addition, it offers children’s nutrition products comprising products for meeting children’s nutritional needs at toddlers and older children stage, as well as offer milk modifiers under the Enfagrow, Sustagen, Lactum, ChocoMilk, and Cal-C-Tose names; a range of other products, including pre-natal and post-natal nutritional supplements for expectant and nursing mothers under the Expecta and EnfaMama names; and pediatric vitamin products under the Enfamil Poly-Vi-Sol name, as well as multivitamins and iron supplements for infants. The company sells its products to mothers, health care professionals, and retailers in approximately 50 countries in Asia, North America, Latin America, and Europe. Mead Johnson Nutrition Company was founded in 1905 and is headquartered in Glenview, Illinois.

Pfizer Inc. (PFE) gained $0.06 to close the day at a new closing price of $31.73, a 0.19% increase in value from its previous closing price that moved the stock 16.58% above its 52 week low of $28.25. A total of 23.36M shares exchanged hands during the day compared with its three month average trading volume of 28.21M. The stock, which fluctuated between $31.32 and $31.73 during the day, currently situated -12.7% below its 52 week high. The stock is down by -2.87% in the past one month and up by 4.19% over the past three months. With a one year target estimate of $37.52 and RSI of 51.72, the stock still has upside potential, making it a hold for now.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh; and a strategic collaboration agreement with IGNITE Immunotherapy Inc. It also has a collaboration with AbCellera Biologics Inc. to discover therapeutic antibodies against undisclosed membrane protein targets. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

General Electric Company (GE) shares were down in last trading by -0.03% to $29.68. It experienced lighter than average volume on day. The stock decreased in value by almost -2.11% over the past week and fell -6.34% in the past month. It is currently trading -4.94% below its 50 day moving average and -2.55% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -9.36% decrease in value from its one year high of $33. The RSI indicator value of 28.84, lead us to believe that it may correct downwards in the near term.

General Electric Company operates as an infrastructure and financial services company worldwide. Its Power segment offers gas and steam power systems; maintenance, service, and upgrade solutions; distributed power gas engines; water treatment, wastewater treatment, and process system solutions; and nuclear reactors, fuels, and support services. The company’s Renewable Energy segment offers wind turbine platforms, and hardware and software; offshore wind turbines; and solutions, products, and services to hydropower industry. Its Oil and Gas segment offers turbomachinery solutions; surface and subsea drilling and production systems, and equipment for floating production platforms; measurement and control products; and compressors, pumps, valves, and natural gas solutions. The company’s Energy Management segment offers industrial and grid solutions, and power conversion systems. Its Aviation segment designs and produces commercial and military aircraft engines, integrated digital components, electric power, and mechanical aircraft systems; and offers aftermarket services. The company’s Healthcare segment offers diagnostic imaging and clinical systems; products for drug discovery, biopharmaceutical manufacturing, and cellular technologies; and healthcare information technology products. Its Transportation segment offers freight and passenger locomotives, parts, wreck repair, software-enabled solutions, mining equipment and services, marine diesel engines, and stationary power diesel engines and motors, as well as overhaul, repair, and upgrade services. GE’s Appliances & Lighting segment sells and services home appliances; and manufactures, sources, and sells lighting solutions. Its Capital segment offers commercial lending and leasing, factoring, energy financial, and aircraft financing and leasing services. GE also designs powder bed-based laser additive manufacturing machines. The company was founded in 1892 and is headquartered in Fairfield, Connecticut.

 

3 Stocks in Focus: Pfizer Inc. (PFE), Ecolab Inc. (ECL), The Hershey Company (HSY)

Pfizer Inc. (PFE) climbed 1.34% during last trading as the stock added $0.42 to finish the day at $31.73 with about 37.42M shares changing hands, compared to its three month average trading volume of 28.33M. The $192.55B market cap company, which fluctuated between $30.93 and $31.93 during the day, currently situated 15.41% above its 52 week low of $28.25 and -13.58% away from its one year high of $37.39. The RSI of 44.51 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh; and a strategic collaboration agreement with IGNITE Immunotherapy Inc. It also has a collaboration with AbCellera Biologics Inc. to discover therapeutic antibodies against undisclosed membrane protein targets. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Ecolab Inc. (ECL) dropped $-1.36 to close the day at a new closing price of $120.13, a -1.12% decrease in value from its previous closing price that moved the stock 23.32% above its 52 week low of $98.62. A total of 1.09M shares exchanged hands during the day compared with its three month average trading volume of 963.35K. The stock, which fluctuated between $119.77 and $121.75 during the day, currently situated -3.01% below its 52 week high. The stock is up by 2.06% in the past one month and up by 4.69% over the past three months. With a one year target estimate of $122.33 and RSI of 54.13, the stock still has upside potential, making it a hold for now.

Ecolab Inc. provides water, hygiene, and energy technologies and services for customers worldwide. The company operates in three segments: Global Industrial, Global Institutional, and Global Energy. The Global Industrial segment provides water treatment and process applications, and cleaning and sanitizing solutions primarily to large industrial customers within the manufacturing, food and beverage processing, chemical, mining and primary metals, power generation, pulp and paper, and commercial laundry industries. The Global Institutional segment offers specialized cleaning and sanitizing products to the foodservice, hospitality, lodging, healthcare, government and education, and retail industries. The Global Energy segment provides the process chemicals and water treatment needs of the petroleum and petrochemical industries in upstream and downstream applications. The company also offers pest elimination services, such as detection, eliminate, and prevent pests, such as rodents and insects, in restaurants, food and beverage processors, educational and healthcare facilities, hotels, quick service restaurant and grocery operations, and other institutional and commercial customers; and equipment repair, maintenance and preventive maintenance services for the commercial food service industry. The company sells its products through company-employed field sales personnel, corporate account personnel, distributors, and dealers. Ecolab Inc. was founded in 1923 and is headquartered in St. Paul, Minnesota.

The Hershey Company (HSY) had a active trading with around 1.7M shares changing hands compared to its three month average trading volume of 1.04M. The stock traded between $105.05 and $106.3 before closing at the price of $105.47 with 0.38% change on the day. The Hershey Pennsylvania 17033 based company is currently trading 23.71% above its 52 week low of $86.64 and -9.4% below its 52 week high of $117.79. Both the RSI indicator and target price of 60.91 and $103.47 respectively, lead us to believe that it should be put on hold over the coming weeks.

The Hershey Company manufactures, imports, markets, distributes, and sells confectionery products. The company operates through two segments, North America, and International and Other. It offers chocolate and non-chocolate confectionery products; gum and mint refreshment products comprising chewing gums and bubble gums; pantry items, such as baking ingredients, toppings, beverages, and sundae syrups; and snack items, including spreads, meat snacks, bars and snack bites, and mixes. The company provides its products primarily under the Hershey’s, Reese’s, Kisses, Jolly Rancher, Almond Joy, Brookside, Cadbury, Good & Plenty, Heath, Kit Kat, Lancaster, Payday, Rolo, Twizzlers, Whoppers, York, Scharffen Berger, Dagoba, Ice Breakers, Breathsavers, and Bubble Yum brands, as well as under the Golden Monkey, Pelon Pelo Rico, IO-IO, Nutrine, Maha Lacto, Jumpin, and Sofit brands. It markets and sells its products to wholesale distributors, chain grocery stores, mass merchandisers, chain drug stores, vending companies, wholesale clubs, convenience stores, dollar stores, concessionaires, and department stores. The Hershey Company was founded in 1894 and is headquartered in Hershey, Pennsylvania.

 

3 Stocks to Watch For: Pfizer Inc. (PFE), QUALCOMM Incorporated (QCOM), Bristol-Myers Squibb Company (BMY)

Pfizer Inc. (PFE) saw its value increase by 0.45% as the stock gained $0.14 to finish the day at a closing price of $31.42. The stock was lighter in trading and has fluctuated between $28.25-$37.39 per share for the past year. The shares, which traded within a range of $31.26 to $31.54 during the day, are down by -2.06% in the past three months and down by -12.74% over the past six months. It is currently trading -3.07% below its 20 day moving average and -2.35% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $37.52 a share over the next twelve months. The current relative strength index (RSI) reading is 38.11.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh; and a strategic collaboration agreement with IGNITE Immunotherapy Inc. It also has a collaboration with AbCellera Biologics Inc. to discover therapeutic antibodies against undisclosed membrane protein targets. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

QUALCOMM Incorporated (QCOM) shares were up in last trading by 0.35% to $54.24. It experienced higher than average volume on day. The stock decreased in value by almost -13.74% over the past week and fell -19.35% in the past month. It is currently trading -17.32% below its 50 day moving average and -9.81% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -23.67% decrease in value from its one year high of $71.62. The RSI indicator value of 25.25, lead us to believe that it may correct downwards in the near term.

QUALCOMM Incorporated develops, designs, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, the United States, and internationally. The company operates through three segments: Qualcomm CDMA Technologies (QCT); Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on code division multiple access (CDMA), orthogonal frequency division multiple access (OFDMA), and other technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses or provides rights to use portions of its intellectual property portfolio, which include various patent rights useful in the manufacture and sale of certain wireless products comprising products implementing CDMA2000, WCDMA, CDMA TDD, and/or LTE standards, as well as their derivatives. The QSI segment invests in early-stage companies in various industries, including digital media, e-commerce, healthcare, and wearable devices for supporting the design and introduction of new products and services for voice and data communications. The company also develops and offers products for implementation of small cells; mobile health products and services; software products, and content and push-to-talk enablement services to wireless operators; and development, and other services and related products to the United States government agencies and their contractors. In addition, it licenses chipset technology and products for data centers. QUALCOMM Incorporated was founded in 1985 and is headquartered in San Diego, California.

Bristol-Myers Squibb Company (BMY) traded within a range of $47.12 to $48.62 after opening the day at $47.26. The company has seen its stock decrease in value by -17.77% so far this year. The stock was up close to 1.96% on active volume in last trading session and closed at $47.74 per share. After the recent gain, the stock is currently holding -37.26% below its 52 week high of $77.12 and 3.76% above its 12-month low of $46.01. The shares are down by over -2.51% in the last three months, and the RSI indicator value of 25.76 is bullish. They are not pointing to a rebound in the stock. We should get in as it looks to have found a bottom.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

 

3 Stocks to Watch For: Wells Fargo & Company (WFC), Pfizer Inc. (PFE), Micron Technology, Inc. (MU)

Wells Fargo & Company (WFC) saw its value increase by 3.51% as the stock gained $1.92 to finish the day at a closing price of $56.62. The stock was higher in trading and has fluctuated between $43.55-$58.02 per share for the past year. The shares, which traded within a range of $55.28 to $56.83 during the day, are up by 25.42% in the past three months and up by 19.97% over the past six months. It is currently trading 2.99% above its 20 day moving average and 4.07% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $57.9 a share over the next twelve months. The current relative strength index (RSI) reading is 61.31.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, as well as time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards. This segment also provides equipment leases, real estate and other commercial financing, small business administration financing, venture capital financing, cash management, payroll services, retirement plans, and merchant payment processing and private label financing solutions, as well as purchases retail installment contracts. Its Wholesale Banking segment offers commercial loans and lines of credit, letters of credit, asset-based lending, equipment leasing, international trade facilities, trade financing, collection, foreign exchange, treasury management, investment management, institutional fixed-income sales, interest rate, commodity and equity risk management, insurance, corporate trust fiduciary and agency, and investment banking services, as well as online/electronic products. This segment also provides construction, and land acquisition and development loans; secured and unsecured lines of credit; interim financing arrangements; rehabilitation loans; affordable housing loans and letters of credit; loans for securitization; commercial real estate loan servicing; and real estate and mortgage brokerage services. The company’s Wealth, Brokerage and Retirement segment offers financial advisory, wealth management, brokerage, retirement, trust, and reinsurance services. As of February 25, 2015, it operated through approximately 8,700 locations and 12,500 ATMs & offices in 36 countries. Wells Fargo & Company was founded in 1852 and is headquartered in San Francisco, California.

Pfizer Inc. (PFE) shares were up in last trading by 0.45% to $31.29. It experienced higher than average volume on day. The stock decreased in value by almost -2.31% over the past week and fell -3.25% in the past month. It is currently trading -2.97% below its 50 day moving average and -5.96% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -14.78% decrease in value from its one year high of $37.39. The RSI indicator value of 34.75, lead us to believe that it is a hold for now.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh; and a strategic collaboration agreement with IGNITE Immunotherapy Inc. It also has a collaboration with AbCellera Biologics Inc. to discover therapeutic antibodies against undisclosed membrane protein targets. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Micron Technology, Inc. (MU) traded within a range of $23.19 to $23.98 after opening the day at $23.4. The company has seen its stock increase in value by 7.48% so far this year. The stock was up close to 3.11% on active volume in last trading session and closed at $23.56 per share. After the recent gain, the stock is currently holding -0.34% below its 52 week high of $23.98 and 151.98% above its 12-month low of $9.35. The shares are up by over 38.1% in the last three months, and the RSI indicator value of 64.59 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Micron Technology, Inc. provides semiconductor systems worldwide. The company operates through four segments: Compute and Networking Business Unit, Storage Business Unit, Mobile Business Unit, and Embedded Business Unit. It offers DDR3 and DDR4 DRAM products for computers, servers, networking devices, communications equipment, consumer electronics, automotive, and industrial applications; mobile low-power DRAM products for smartphones, tablets, automotive, laptop computers, and other mobile consumer device applications; DDR2 and DDR DRAM, GDDR5 and GDDR5X DRAM, SDRAM, and RLDRAM products for networking devices, servers, consumer electronics, communications equipment, computer peripherals, automotive and industrial applications, and computer memory upgrades; and hybrid memory cube semiconductor memory devices for use in networking and computing applications. The company also provides NAND Flash products, which are electrically re-writeable, non-volatile semiconductor memory devices; client solid-state drives (SSDs) for notebooks, desktops, workstations, and other consumer applications; enterprise SSDs for server and storage applications; managed multi-chip package products; digital media products, including flash memory cards and JumpDrive products under the Lexar brand name. In addition, it manufactures products that are sold under other brand names; and resells flash memory products that are purchased from other NAND Flash suppliers. Further, the company provides 3D XPoint memory products; and NOR Flash, which are electrically re-writeable and semiconductor memory devices for automotive, industrial, connected home, and consumer applications. It markets its products to original equipment manufacturers and retailers through its internal sales force, independent sales representatives, and distributors; and through a Web-based customer direct sales channel, and channel and distribution partners. The company was founded in 1978 and is headquartered in Boise, Idaho.

 

3 Trending Stocks: Ford Motor Company (F), General Electric Company (GE), Pfizer Inc. (PFE)

Ford Motor Company (F) managed to rebound with the stock climbing 2.44% or $0.3 to close the day at $12.61 on light trading volume of 34.54M shares, compared to its three month average trading volume of 37.05M. The Dearborn Michigan 48126 based company has been outperforming the auto manufacturers – major group over the past 52 weeks, with the stock gaining 14.42%, compared to the industry which has advanced 23.39% over the same period. With RSI of 57.9, the stock should still continue to rise and get closer to its one year target estimate of $12.83, making it a hold for now.

Ford Motor Company, together with its subsidiaries, designs, manufactures, markets, finances, and services automobiles. The company operates through two sectors, Automotive and Financial Services. The Automotive sector develops, manufactures, distributes, and services passenger cars, trucks, SUVs, light commercial vehicles, trucks, vans, and electrified vehicles, as well as offers parts and accessories. It offers vehicles primarily under the Ford and Lincoln brand names. This sector markets and sells its products through distributors and dealers, as well as through dealerships to fleet customers, including commercial fleet customers, daily rental car companies, and governments. The Financial Services sector offers various automotive financing products to and through automotive dealers. It provides financing products, including retail installment sale contracts for new and used vehicles; and direct financing leases for new vehicles to retail and commercial customers, government entities, daily rental car companies, leasing companies, and fleet customers. This sector also offers wholesale loans to dealers to finance the purchase of vehicle inventory; and loans to dealers to finance working capital and improvement of dealership facilities, purchase dealership real estate, and other dealer vehicle programs. It serves clients in North America, South America, Europe, the Middle East, Africa, and the Asia Pacific. Ford Motor Company was founded in 1903 and is based in Dearborn, Michigan.

General Electric Company (GE) climbed 0.84% during last trading as the stock added $0.25 to finish the day at $30 with about 31.9M shares changing hands, compared to its three month average trading volume of 32.8M. The $271.3B market cap company, which fluctuated between $29.82 and $30.06 during the day, currently situated 13.31% above its 52 week low of $27.1 and -8.38% away from its one year high of $33. The RSI of 27.98 indicates the stock is oversold at the current levels, buy for now.

General Electric Company operates as an infrastructure and financial services company worldwide. Its Power segment offers gas and steam power systems; maintenance, service, and upgrade solutions; distributed power gas engines; water treatment, wastewater treatment, and process system solutions; and nuclear reactors, fuels, and support services. The company’s Renewable Energy segment offers wind turbine platforms, and hardware and software; offshore wind turbines; and solutions, products, and services to hydropower industry. Its Oil and Gas segment offers turbomachinery solutions; surface and subsea drilling and production systems, and equipment for floating production platforms; measurement and control products; and compressors, pumps, valves, and natural gas solutions. The company’s Energy Management segment offers industrial and grid solutions, and power conversion systems. Its Aviation segment designs and produces commercial and military aircraft engines, integrated digital components, electric power, and mechanical aircraft systems; and offers aftermarket services. The company’s Healthcare segment offers diagnostic imaging and clinical systems; products for drug discovery, biopharmaceutical manufacturing, and cellular technologies; and healthcare information technology products. Its Transportation segment offers freight and passenger locomotives, parts, wreck repair, software-enabled solutions, mining equipment and services, marine diesel engines, and stationary power diesel engines and motors, as well as overhaul, repair, and upgrade services. GE’s Appliances & Lighting segment sells and services home appliances; and manufactures, sources, and sells lighting solutions. Its Capital segment offers commercial lending and leasing, factoring, energy financial, and aircraft financing and leasing services. GE also designs powder bed-based laser additive manufacturing machines. The company was founded in 1892 and is headquartered in Fairfield, Connecticut.

Pfizer Inc. (PFE) saw its value decrease by -0.99% as the stock dropped $-0.31 to finish the day at a closing price of $31.15. The stock was higher in trading and has fluctuated between $28.25-$37.39 per share for the past year. The shares, which traded within a range of $30.9 to $31.46 during the day, are down by -2.24% in the past three months and down by -13.75% over the past six months. It is currently trading -4.44% below its 20 day moving average and -3.46% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $37.57 a share over the next twelve months. The current relative strength index (RSI) reading is 31.47. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh; and a strategic collaboration agreement with IGNITE Immunotherapy Inc. It also has a collaboration with AbCellera Biologics Inc. to discover therapeutic antibodies against undisclosed membrane protein targets. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

 

3 Trending Stocks: Marinus Pharmaceuticals, Inc. (MRNS), AT&T Inc. (T), Pfizer Inc. (PFE)

Marinus Pharmaceuticals, Inc. (MRNS) managed to rebound with the stock climbing 18.1% or $0.21 to close the day at $1.37 on light trading volume of 27.04M shares, compared to its three month average trading volume of 912.60K. The Radnor Pennsylvania 19087 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -77.76%, compared to the industry which has advanced 0.26% over the same period. With RSI of 66.62, the stock should still continue to rise and get closer to its one year target estimate of $3.33, making it a hold for now.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.

AT&T Inc. (T) climbed 1.33% during last trading as the stock added $0.55 to finish the day at $42 with about 25.17M shares changing hands, compared to its three month average trading volume of 25.44M. The $259.06B market cap company, which fluctuated between $41.39 and $42.07 during the day, currently situated 30.29% above its 52 week low of $34.9 and -1.26% away from its one year high of $43.89. The RSI of 63.72 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

AT&T Inc. provides telecommunications and digital entertainment services. The company operates through four segments: Business Solutions, Entertainment Group, Consumer Mobility, and International. The Business Solutions segment offers wireless, fixed strategic, legacy voice and data, and wireless equipment services to business, governmental, and wholesale customers, as well as individual subscribers. The Entertainment Group segment provides video entertainment and audio programming channels to approximately 25.4 million subscribers; broadband and Internet services to 12.4 million residential subscribers; local and long-distance voice services to residential customers, as well as DSL Internet access services; and voice services over IP-based technology, and technical support and other customer service functions and equipment. The Consumer Mobility segment offers wireless services to consumers, and wireless wholesale and resale subscribers, such as long-distance and roaming services. This segment provides postpaid and prepaid wireless voice and data communications services; consulting, advertising, and application and co-location services; and sells a variety of handsets, wirelessly enabled computers, and personal computer wireless data cards through company-owned stores, agents, or third-party retail stores, as well as accessories, such as carrying cases and hands-free devices. The International segment offers video entertainment services to residential customers in Latin America, as well as wireless data and voice communication services in Mexico. This segment provides digital television services under the DIRECTV and SKY brands; postpaid and prepaid wireless services to approximately 8.7 million subscribers under the AT&T, Iusacell, Unefon, and Nextel Mexico brands; and sells a range of handsets. The company was formerly known as SBC Communications Inc. and changed its name to AT&T Inc. in November 2005. AT&T Inc. was founded in 1983 and is based in Dallas, Texas.

Pfizer Inc. (PFE) saw its value decrease by -0.98% as the stock dropped $-0.31 to finish the day at a closing price of $31.46. The stock was lighter in trading and has fluctuated between $28.25-$37.39 per share for the past year. The shares, which traded within a range of $31.44 to $31.82 during the day, are down by -2.35% in the past three months and down by -12.8% over the past six months. It is currently trading -3.63% below its 20 day moving average and -2.41% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $37.57 a share over the next twelve months. The current relative strength index (RSI) reading is 34.1. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh; and a strategic collaboration agreement with IGNITE Immunotherapy Inc. It also has a collaboration with AbCellera Biologics Inc. to discover therapeutic antibodies against undisclosed membrane protein targets. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.